Fate Therapeutics (NASDAQ:FATE – Get Free Report) announced its quarterly earnings data on Monday. The biopharmaceutical company reported ($0.45) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.12, MarketWatch Earnings reports. Fate Therapeutics had a negative return on equity of 36.63% and a negative net margin of 253.30%. The company […]

Related Keywords

Bahram Valamehr , Vanguard Group Inc , Fate Therapeutics Company Profile , Morgan Stanley , Blackrock Inc , Securities Exchange Commission , Redmile Group Llc , Wells Fargo Company , Fate Therapeutics Inc , Pricet Rowe Associates Inc , Fate Therapeutics , Get Free Report , Marketwatch Earnings , Therapeutics Trading Down , Director Redmile Group , Exchange Commission , Street Corp , Capital World Investors , World Investors , Wells Fargo , Fate Therapeutics Daily ,